Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00711
|
|||||
| Drug Name |
Vemurafenib
|
|||||
| Synonyms |
PLX4032; RG7204; RO5185426; Vemurafenib (BRAF inhibitor); Zelboraf (TN)
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Metastatic melanoma [ICD11: 2C30] | Approved | [1] | |||
| Thyroid cancer [ICD11: 2D10] | Approved | [1] | ||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C23H18ClF2N3O3S
|
|||||
| Canonical SMILES |
CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(C=C4)Cl)F
|
|||||
| InChI |
InChI=1S/C23H18ClF2N3O3S/c1-2-9-33(31,32)29-19-8-7-18(25)20(21(19)26)22(30)17-12-28-23-16(17)10-14(11-27-23)13-3-5-15(24)6-4-13/h3-8,10-12,29H,2,9H2,1H3,(H,27,28)
|
|||||
| InChIKey |
GPXBXXGIAQBQNI-UHFFFAOYSA-N
|
|||||
| CAS Number |
CAS 918504-65-1
|
|||||
| Pharmaceutical Properties | Molecular Weight | 489.9 | Topological Polar Surface Area | 100 | ||
| Heavy Atom Count | 33 | Rotatable Bond Count | 7 | |||
| Hydrogen Bond Donor Count | 2 | Hydrogen Bond Acceptor Count | 7 | |||
| XLogP |
5
|
|||||
| PubChem CID | ||||||
| PubChem SID |
104245715
, 123055406
, 123393726
, 124757131
, 125163935
, 125240992
, 125312523
, 125477821
, 126731467
, 131408691
, 131480743
, 134213431
, 135267495
, 135360056
, 135611115
, 135626717
, 135686206
, 135686207
, 135686222
, 135686223
, 135727433
, 136367377
, 136920367
, 137241152
, 137275900
, 138196197
, 152258377
, 160647214
, 160837190
, 162011358
, 162037528
, 162201724
, 163098027
, 163345507
, 163390276
, 164041819
, 164193918
, 164766097
, 164834160
, 165826640
, 170483525
, 170498105
, 172087033
, 172914376
, 174531480
, 175267423
, 86450036
, 99207986
, 99344329
, 99436933
|
|||||
| ChEBI ID |
ChEBI:63637
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | OATP1B1 | Transporter Info | Organic anion transporting polypeptide 1B1 | Substrate | [2] | |
| OATP1B3 | Transporter Info | Organic anion transporting polypeptide 1B3 | Substrate | [2] | ||
| P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [3] | ||
| References | ||||||
| 1 | Vemurafenib was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin Cancer Res. 2013 Mar 15;19(6):1458-66. | |||||
| 3 | Differential effects of the oncogenic BRAF inhibitor PLX4032 (vemurafenib) and its progenitor PLX4720 on ABCB1 function. J Pharm Pharm Sci. 2014;17(1):154-68. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.